Press release
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including Epidermolysis Bullosa clinical trials and nonclinical stage products. It also covers the Epidermolysis Bullosa therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key Takeaways from the Epidermolysis Bullosa Pipeline Report
• DelveInsight's Epidermolysis Bullosa pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Epidermolysis Bullosa treatment.
• The leading companies working in the Epidermolysis Bullosa Market include Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Aegle Therapeutics, Phoenix Tissue Repair Inc., Lenus Therapeutics LLC, Wings Therapeutics Inc., Krystal Biotech Inc., Onconova Therapeutics Inc., InMed Pharmaceuticals Inc., Constant Therapeutics, Kangstem Biotech, ProQR Therapeutics, Ishin Pharmaceutical, and others.
• Promising Epidermolysis Bullosa Pipeline Therapies in the various stages of development include SD-101-6.0 cream, diacerein 1% ointment, allo-APZ2-OTS, PTR-01, Oleogel-S10, FCX-007, and others.
• August 2023: Anterogen Co. Ltd announced a study of phase 1 & 2 clinical trials for Allogeneic mesenchymal stem cells and Polyurethene Film. This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Dystrophic Epidermolysis Bullosa.
• September 2023: BioMendics LLC announced a study of phase 1 clinical trials for TolaSure Topical Gel and Vehicle Topical Gel. TolaSure is a topical gel for the promotion of accelerated wound healing. This Phase I study will assess the safety, tolerability, and clinical effects of TolaSure when applied to wounded skin areas of patients diagnosed with severe epidermolysis bullosa simplex (i.e., EBS-Dowling Meara). A total of 10, severe EBS patients, males and females ages 18 years and older, will be enrolled.
Request a sample and discover the recent advances in Epidermolysis Bullosa Treatment Drugs @ Epidermolysis Bullosa Pipeline Report- https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Epidermolysis Bullosa pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Epidermolysis Bullosa clinical trials studies, Epidermolysis Bullosa NDA approvals (if any), and product development activities comprising the technology, Epidermolysis bullosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Epidermolysis Bullosa Overview
Epidermolysis bullosa (EB) is a genetic skin disorder characterized clinically by blister formation from mechanical trauma. There are four main types with additional sub-types identified. There is a spectrum of severity, and within each type, one may be either mildly or severely affected.
Find out more about Epidermolysis Bullosa Therapeutics Assessment @ Epidermolysis Bullosa Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Epidermolysis Bullosa Emerging Drugs Profile
• EB-101: Abeona Therapeutics
• D-Fi (FCX-007): Castle Creek Biosciences
Epidermolysis Bullosa Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the Epidermolysis Bullosa therapies. The Epidermolysis Bullosa companies which have their Epidermolysis Bullosa drug candidates in the most advanced stage, i.e. phase III include, Abeona Therapeutics.
Learn more about the emerging Epidermolysis Bullosa Pipeline Therapies @ Epidermolysis Bullosa Clinical Trials Assessment- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Epidermolysis Bullosa Pipeline Report
• Coverage- Global
• Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Epidermolysis Bullosa Companies- Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Aegle Therapeutics, Phoenix Tissue Repair Inc., Lenus Therapeutics LLC, Wings Therapeutics Inc., Krystal Biotech Inc., Onconova Therapeutics Inc., InMed Pharmaceuticals Inc., Constant Therapeutics, Kangstem Biotech, ProQR Therapeutics, Ishin Pharmaceutical, and others.
• Epidermolysis Bullosa Pipeline Therapies- SD-101-6.0 cream, diacerein 1% ointment, allo-APZ2-OTS, PTR-01, Oleogel-S10, FCX-007, and others.
Dive deep into rich insights for new drugs for Epidermolysis Bullosa treatment, Visit @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Epidermolysis bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. EB-101: Abeona Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. PTR-01: Phoenix Tissue Repair
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. Drug Name: Product Name
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. TXA127: Constant Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Epidermolysis bullosa Key Companies
20. Epidermolysis bullosa Key Products
21. Epidermolysis bullosa- Unmet Needs
22. Epidermolysis bullosa- Market Drivers and Barriers
23. Epidermolysis bullosa- Future Perspectives and Conclusion
24. Epidermolysis bullosa Analyst Views
25. Epidermolysis bullosa Key Companies
26. Appendix
For further information on the Epidermolysis Bullosa pipeline therapeutics, reach out to Epidermolysis Bullosa Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Published Important Links-
https://huggingface.co/dennydones9
https://www.jumpinsport.com/users/dennydones9
https://cybrvrs3.mn.co/posts/what-are-the-hot-flashes-in-prostate-cancer-market
https://myparea.mn.co/posts/44420239
https://comidarealkitchen.mn.co/posts/44420336
https://yizhanverse.mn.co/posts/what-is-the-hot-flashes-in-prostate-cancer-market-forecast
https://bookmarkswing.com/story16980789/hot-flashes-in-prostate-cancer-market
https://bookmarkspring.com/story10356297/hot-flashes-in-prostate-cancer-market-size
https://www.komoot.com/user/3809450162854
https://maphub.net/dennydones9
https://digitaldrip.mn.co/posts/44423215
https://ultraplus.mn.co/posts/44423326
https://veganxyz.mn.co/posts/44423488
https://ourclass.mn.co/posts/about-hot-flashes-in-prostate-cancer-market-size
https://diecast64.mn.co/posts/44423854
https://the-trifecta-network.mn.co/posts/44424109
https://talenthopper.mn.co/posts/44424433
https://thegameoflife-de.mn.co/posts/44424538
https://monvelli.mn.co/posts/44424617
https://mighty-men.mn.co/posts/44424691
https://jobs.recruitingblogs.com/employers/2384764-delveinsight
http://samus.vforums.co.uk/profile/dennydonesdi
http://supportskin.vforums.co.uk/profile/dennydonesdi
http://wwa.vforums.co.uk/profile/dennydonesdi
http://music.vforums.co.uk/general/2838/delveinsight
http://nuchinuxri.vforums.co.uk/profile/dennydones91021
http://raf.vforums.co.uk/profile/dennydonesdi
http://france.vforums.co.uk/Suggestions/1797/market-research-reports
http://thecir.vforums.co.uk/profile/dennydonesdi
http://lol.vforums.co.uk/profile/dennydonesdi
https://www.openlearning.com/u/havensmith-s2ry19/
https://dennydones9.cgsociety.org/profile
https://www.f6s.com/member/denny-dones
https://www.minecraftforum.net/members/dennydones9?__cf_chl_tk=ljVLvJPBSq9.mVHsoWgwPjJb0A23nSrkftR8IxJ5Wec-1697717482-0-gaNycGzNDTs
https://coderwall.com/p/4tufta/herpes-zoster-market-trends-and-developments-in-2023
https://midi.org/forum/20192-herpes-zoster-market-future-prospects-in-2023
https://tapas.io/ybhardwaj
https://photozou.jp/user/top/3328982
https://b.hatena.ne.jp/entry?url=https%3A%2F%2Fwww.delveinsight.com%2Freport-store%2Fherpes-zoster-market
https://www.thingiverse.com/dennydones9/designs
https://soundcloud.com/dennydones
https://experiment.com/users/dennydones9
https://lichess.org/@/dennydones9
https://www.nicovideo.jp/user/130955053
https://menwiki.men/wiki/Main_Page
https://historydb.date/wiki/2_Bonus_Paling_Penting_di_Agen_Sbobet88_Terpercaya
https://mozillabd.science/wiki/Main_Page
https://championsleage.review/wiki/Main_Page
https://timeoftheworld.date/wiki/Main_Page
https://funsilo.date/wiki/Main_Page
https://opensourcebridge.science/wiki/Main_Page
https://scientific-programs.science/wiki/Main_Page
https://lovewiki.faith/wiki/Main_Page
https://influence.co/dennydones9999
https://www.awwwards.com/dennydones9999/
https://www.producthunt.com/discussions/pharma-competitive-intelligence-tracking-services-navigating-the-pharmaceutical-landscape
https://forum.ngs.ru/profile/3132957/
https://zrzutka.pl/profile/delveinsight-295941
https://sound-social.com/story5059347/healthcare-competitive-intelligence-tracking-services
https://socialmarkz.com/story5419072/healthcare-competitive-intelligence-tracking-services
https://network-373.mn.co/posts/41603294
https://www.hogwartsishere.com/1562170/
https://www.renderosity.com/users/id:1400373
https://hitrecord.org/users/dennydones9999/records
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.atlasobscura.com/users/dennydones1
https://freedomlifestyle.mn.co/posts/41604435
https://socialmediainuk.com/story15310402/healthcare-competitive-intelligence-tracking-services
https://onlinedhan.mn.co/posts/41604571
https://skeleton-girls.mn.co/posts/41716585
https://network-89593.mn.co/posts/41716670
https://shaman-leaders.mn.co/posts/41716806
https://walkinvirtualclinics.mn.co/posts/41716883
https://machineintelligence.mn.co/posts/the-role-of-healthcare-partner-identification-services
https://vjudge.net/user/dennydones9999
https://yizhanverse.mn.co/posts/41717293
https://demo.plushforums.com/profile/18/denny-dones
https://www.sideprojectors.com/user/profile/69119
https://bookmarkstumble.com/story16655285/healthcare-partner-identification-services
https://bookmarkstime.com/story15535182/healthcare-partner-identification-services
http://baigasciedil.vforums.co.uk/profile/dennydones9999
http://weareone.vforums.co.uk/profile/dennydones9999
http://astarsuzuki.vforums.co.uk/profile/dennydones9999
http://proweb.vforums.co.uk/action/view_profile/user/dennydones9999
http://taresources.vforums.co.uk/action/view_profile/user/dennydones9999
http://gothicskin.vforums.co.uk/profile/dennydones9999
http://graphics.vforums.co.uk/profile/dennydones9999
http://clapecasna.vforums.co.uk/profile/dennydones9999
http://freuniontest.vforums.co.uk/profile/dennydones9999
http://whatwentwrong.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://system.vforums.co.uk/profile/dennydones9999
http://upsclan.vforums.co.uk/profile/dennydones999911
http://hairetevi.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://vfscomp2.vforums.co.uk/profile/dennydones9999
http://gamersgetaway.vforums.co.uk/profile/dennydones9999
http://surreyjobs.vforums.co.uk/profile/dennydones9999
http://support2.vforums.co.uk/profile/dennydones9999
http://swlsupport.vforums.co.uk/profile/dennydones9999
http://slipalimer.vforums.co.uk/profile/dennydones990099
http://art.vforums.co.uk/profile/dennydones990099
http://styles.vforums.co.uk/profile/dennydones990099
http://ghofertech.vforums.co.uk/profile/dennydones990099
http://dcdesign.vforums.co.uk/profile/dennydones990099
http://musicspot.vforums.co.uk/profile/dennydones990099
http://prov.vforums.co.uk/profile/dennydones990099
http://russell.vforums.co.uk/profile/dennydones990099
http://makethemes.vforums.co.uk/profile/dennydones990099
http://famousads.vforums.co.uk/profile/dennydones990099
http://pinkness.vforums.co.uk/profile/dennydones990011
http://elseandrew.vforums.co.uk/profile/dennydones99
http://suigacartsing.vforums.co.uk/profile/dennydones99
http://calanaera.vforums.co.uk/profile/dennydones99
http://legstudios.vforums.co.uk/action/view_profile/user/dennydones99
http://idirectory-old.vforums.co.uk/profile/dennydones99
http://skegness.vforums.co.uk/profile/dennydones99
http://futurexistence.vforums.co.uk/action/view_profile/user/dennydones99
http://codes.vforums.co.uk/profile/dennydones99
http://isgicaflo.vforums.co.uk/profile/dennydones99
http://profewovxi.vforums.co.uk/profile/dennydones99
http://zacsplace.vforums.co.uk/profile/dennydones99
http://sneeznavilas.vforums.co.uk/profile/dennydones99
http://coderspalace.vforums.co.uk/profile/dennydones991199
http://guide.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://rs2devolution.vforums.co.uk/action/view_profile/user/dennydones99
http://englishporcelain.vforums.co.uk/profile/dennydones99
https://scratchgram-2nd-instagram2.mn.co/posts/navigating-the-healthcare-landscape-with-competitive-intelligence-tracking-services
https://network-84066.mn.co/posts/42686849
https://www.canadavideocompanies.ca/author/dennydones1/
https://monvelli.mn.co/posts/42687788
https://fishjines.mn.co/posts/42688039
https://diecast64.mn.co/posts/42688112
https://mighty-men.mn.co/posts/42688183
https://team-clo.mn.co/posts/unveiling-the-power-of-healthcare-competitive-intelligence-tracking-services
https://stackoverflow.com/users/22614429/denny-dones?tab=profile
https://waarnemingen.be/users/791405/
https://keywebco.mn.co/posts/healthcare-competitive-intelligence-tracking-services-unveiling-the-future-of-healthcare-strategy
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated) here
News-ID: 3271196 • Views: …
More Releases from DelveInsight Business Research LLP

Colorectal Cancer Pipeline Drugs in Development Signal Major Shifts in the Treat …
DelveInsight's, "Colorectal Cancer Pipeline Insight 2025" report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Colorectal…

Idiopathic Pulmonary Fibrosis Pipeline Clinical Trial Insights Reveal Breakthrou …
DelveInsight's, "Idiopathic Pulmonary Fibrosis Pipeline Insights 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Idiopathic Pulmonary Fibrosis pipeline products in this…

Small Cell Lung Cancer Pipeline Clinical Trials Highlight Promising Drugs in Dev …
DelveInsight's, "Small Cell Lung Cancer Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…

Myelofibrosis Pipeline Outlook 2025: Insights Into Therapies, Research, and Mark …
DelveInsight's, "Myelofibrosis Pipeline Insights 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis Pipeline…
More Releases for Epidermolysis
Epidermolysis Bullosa Market to Reach USD 6.8 Billion by 2034
Epidermolysis bullosa (EB) is a group of rare, genetic skin disorders characterized by fragile skin that blisters and tears easily. Often referred to as "the butterfly skin disease," EB significantly impacts patients' quality of life and requires long-term supportive care. Historically, treatments were limited to wound management and pain control, but recent advancements in gene therapy, cell-based therapies, and biologics are opening new possibilities for disease-modifying interventions.
Download Full PDF Sample…
Epidermolysis Bullosa Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Epidermolysis Bullosa Research. Learn more about…
Epidermolysis Bullosa Market to Reach US$ 3,856.2 Million by 2033
Market Overview:
The 7 major epidermolysis bullosa markets reached a value of US$ 2,496.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 3,856.2 Million by 2033, exhibiting a growth rate (CAGR) of 4% during 2023-2033.
The report offers a comprehensive analysis of the epidermolysis bullosa market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as…
Singapore Dystrophic Epidermolysis Bullosa Treatment Market to Observe Strong De …
Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine,…
Epidermolysis Bullosa Market Insights, Share, Size, Companies, and Forecast 2032
DelveInsight's Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermolysis Bullosa Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Epidermolysis Bullosa Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size…
Epidermolysis Bullosa Market Global Research and Clinical Analysis 2021 to 2030
The Epidermolysis Bullosa Market report provides a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Epidermolysis Bullosa study provides comprehensive data which enhances the understanding, scope and application of this report. This report also provides…